Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, has announced its participation in the upcoming 2025 BIO CEO & Investor Conference.
The company's President and CEO, David J. Mazzo, PhD, will deliver a corporate overview presentation on Monday, February 10th at 2:00 p.m. Eastern Time. The conference is scheduled to take place from February 10-11, 2025, at the New York Marriott Marquis in New York City.
Lisata Therapeutics (Nasdaq: LSTA), una società farmaceutica in fase clinica focalizzata sullo sviluppo di terapie innovative per tumori solidi avanzati e altre malattie gravi, ha annunciato la sua partecipazione alla prossima 2025 BIO CEO & Investor Conference.
Il presidente e CEO dell'azienda, David J. Mazzo, PhD, presenterà una panoramica aziendale lunedì 10 febbraio alle 14:00 ora orientale. La conferenza si terrà dal 10 all'11 febbraio 2025, presso il New York Marriott Marquis a New York City.
Lisata Therapeutics (Nasdaq: LSTA), una compañía farmacéutica en etapa clínica enfocada en desarrollar terapias innovadoras para tumores sólidos avanzados y otras enfermedades graves, ha anunciado su participación en la próxima 2025 BIO CEO & Investor Conference.
El presidente y CEO de la compañía, David J. Mazzo, PhD, realizará una presentación sobre la compañía el lunes 10 de febrero a las 2:00 p.m. hora del Este. La conferencia está programada para llevarse a cabo del 10 al 11 de febrero de 2025 en el New York Marriott Marquis en Nueva York.
리사타 테라퓨틱스 (Nasdaq: LSTA), 고급 고형 종양 및 다른 중병에 대한 혁신적인 치료법 개발에 집중하는 임상 단계의 제약 회사가 다가오는 2025 BIO CEO & Investor Conference에 참가한다고 발표했습니다.
회사의 사장 겸 CEO인 David J. Mazzo, PhD가 2025년 2월 10일 월요일 동부 표준시로 오후 2시에 기업 개요 발표를 진행할 예정입니다. 이 회의는 2025년 2월 10일부터 11일까지 뉴욕 시의 뉴욕 메리어트 마르퀴스에서 개최됩니다.
Lisata Therapeutics (Nasdaq: LSTA), une société pharmaceutique en phase clinique axée sur le développement de thérapies innovantes pour des tumeurs solides avancées et d'autres maladies graves, a annoncé sa participation à la prochaine 2025 BIO CEO & Investor Conference.
Le président et CEO de l'entreprise, David J. Mazzo, PhD, présentera un aperçu de l'entreprise le lundi 10 février à 14h00, heure de l'Est. La conférence est prévue du 10 au 11 février 2025, au New York Marriott Marquis à New York.
Lisata Therapeutics (Nasdaq: LSTA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Therapien für fortgeschrittene solide Tumore und andere schwerwiegende Erkrankungen konzentriert, hat seine Teilnahme an der kommenden 2025 BIO CEO & Investor Conference bekannt gegeben.
Der Präsident und CEO des Unternehmens, David J. Mazzo, PhD, wird am Montag, den 10. Februar um 14:00 Uhr Eastern Time eine Unternehmenspräsentation halten. Die Konferenz findet vom 10. bis 11. Februar 2025 im New York Marriott Marquis in New York City statt.
- None.
- None.
BASKING RIDGE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott Marquis in New York City.
Dr. Mazzo’s presentation is scheduled for Monday, February 10th at 2:00 p.m. Eastern Time. For more information about the conference and how to register, please visit https://bcic.bio.org/registration.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Account Supervisor
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com
This press release was published by a CLEAR® Verified individual.
FAQ
When and where will Lisata Therapeutics (LSTA) present at the 2025 BIO CEO Conference?
What will be the focus of Lisata's (LSTA) presentation at the 2025 BIO CEO Conference?
What is Lisata Therapeutics' (LSTA) current business focus?
How long will the 2025 BIO CEO & Investor Conference featuring Lisata (LSTA) run?
